Group Forming in China to Improve Control of Pharmaceutical Excipients
This article was originally published in The Gold Sheet
Group forming in China to improve excipient control.
You may also be interested in...
Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.
Broad agreement across US FDA on modified PQRI recommendations could reduce approval delays over risk of chemicals leaching into parenteral drugs.
Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.